Following radiation therapy with chemotherapy has now been shown to prolong survival for glioma patients. Results of the study were announced Feb. 3 by the National Institutes of Health.

The Scottish developer of optical molecular imaging technology, Edinburgh Molecular Imaging, has received venture capital funding amounting to more than $6 million, the University of Edinburgh announced Feb 7.

Adrenoceptor blockers have been found to stave off metastasis and recurrence of breast cancer. This may be due to their interruption of key genes involved in glucose metabolism as visualized by FDG-PET, according to a study published Feb. 6 in the Journal of Nuclear Medicine.

PET/MR doesn’t appear to provide any additional insight beyond PET/CT for thoracic staging of non-small cell lung cancer, according to a study published Feb. 6 in the Journal of Nuclear Medicine.

Three major patient advocacy associations, the Alzheimer’s Association, the Michael J. Fox Foundation and the W. Garfield Weston Foundation, have joined forces to encourage researchers to explore the biological bridges between Alzheimer’s, Parkinson’s and other neurodegenerative diseases.

The global market for medical reagents, including those used for molecular imaging purposes, is expected to grow substantially through 2016, according to a market report announced Feb. 5 from research firm TechNavio.

FluoroPharma Medical, based in Montclair, N.J., announced yesterday that new results from an ongoing phase II clinical trial for F-18 FCPHA cardiac PET for the diagnosis of acute coronary artery disease (CAD) were positive and providing validation for further research.

A partnership between MPI Research, 3D Imaging and inviCRO has led to a new translational imaging center complete with on-site cyclotron that recently broke ground in Mattawan, Mich. The institution is scheduled to open this spring, according to the Feb. 5 announcement from MPI.